Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - sodium iodide(123i), quantity: 100 mbq - capsule - excipient ingredients: dibasic sodium phosphate heptahydrate; sodium bicarbonate; sodium thiosulfate pentahydrate; sodium hydroxide; purified water; sunset yellow fcf; quinoline yellow; titanium dioxide; brilliant blue fcf; carmoisine; gelatin; ethanol; shellac; pharmaceutical glaze; carbon black - sodium iodide [123] diagnostic capsules are for diagnostic imaging of thyroid tissue.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - sodium iodide(123i), quantity: 1 mbq - capsule - excipient ingredients: dibasic sodium phosphate heptahydrate; sodium bicarbonate; sodium thiosulfate pentahydrate; sodium hydroxide; purified water; sunset yellow fcf; quinoline yellow; titanium dioxide; brilliant blue fcf; carmoisine; gelatin; ethanol; shellac; pharmaceutical glaze; carbon black - sodium iodide [123] diagnostic capsules are for diagnostic imaging of thyroid tissue.

Canada - English - Health Canada

jubilant draximage inc. dba jubilant radiopharma - sodium iodide 131 i - capsule - 7400mbq - sodium iodide 131 i 7400mbq - radioactive agents

Canada - English - Health Canada

jubilant draximage inc. dba jubilant radiopharma - sodium iodide 131 i - solution - 7400mbq - sodium iodide 131 i 7400mbq - radioactive agents

United States - English - NLM (National Library of Medicine)

jubilant draximage inc., dba jubilant radiopharma - sodium iodide i-131 (unii: 29vco8achh) (iodide ion i-131 - unii:4gc1foq22u) - iodide ion i-131 1 mci in 1 ml - hicon® is indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. hicon® is contraindicated in: - patients with vomiting and diarrhea [see warnings and precautions (5.7)] . - patients with thyroid malignancies shown to have no iodide uptake, which include the majority of medullary or anaplastic carcinomas. - patients receiving concurrent anti-thyroid therapy [see warnings and precautions (5.1) and drug interactions (7)] . - pregnancy [see warnings and precautions (5.4), use in specific populations (8.1)] . - lactation [see warnings and precautions (5.5), use in specific populations (8.2)] . risk summary hicon® is contraindicated in pregnancy because fetal exposure can lead to neonatal hypothyroidism, which in some cases is severe and irreversible [see warnings and precautions (5.4)] . data from the published literature describe reports of neonatal thyroid abnormalities after fetal exposure; including agenesis of the thyroid and hypothyroidism (see clinical considerations

Singapore - English - HSA (Health Sciences Authority)

ge healthcare pte. ltd. - sodium iodide [i-131] - injection - 74 mbq/ml - sodium iodide [i-131] 74 mbq/ml

Singapore - English - HSA (Health Sciences Authority)

ge healthcare pte. ltd. - sodium iodide [i-131] - injection - 925 mbq/ml - sodium iodide [i-131] 925 mbq/ml

United States - English - NLM (National Library of Medicine)

ge healthcare, medi-physics, inc. - sodium iodide, i-123 (unii: 29ukx3a616) (sodium iodide, i-123 - unii:29ukx3a616) - capsule - 100 uci - sodium iodide i-123 is indicated for use in the evaluation of thyroid function and/or morphology. none known.

United States - English - NLM (National Library of Medicine)

mallinckrodt nuclear medicine llc - sodium iodide i-131 (unii: 29vco8achh) (iodide ion i-131 - unii:4gc1foq22u) - iodide ion i-131 1 mci in 1 ml

Singapore - English - HSA (Health Sciences Authority)

quantum technologies global pte. ltd. - sodium iodide na131i, solution - capsule - sodium iodide na131i, solution 37-5500 mbq